APTO Aptose Biosciences
- 1.2300
- 0.00000.00%
- 1.2100
- -0.0200-1.63%
Aptose Biosciences News
Calendar of Canada Earnings Expected in the Week Ahead
Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc. Company Symbo
Aptose Biosciences Unveils Q1 Results and Clinical Update
Aptose Biosciences Announces Vital Update; Not SEC Filed
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat
Aptose Biosciences Enhances Executive Compensation and Roles
What Makes Aptose Biosciences (APTO) a New Buy Stock
Aptose Biosciences Is Maintained at Overweight by Piper Sandler
Aptose Biosciences Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Overweight on Aptose Biosciences, Maintains $5 Price Target
Piper Sandler analyst Edward Tenthoff maintains Aptose Biosciences (NASDAQ:APTO) with a Overweight and maintains $5 price target.
Aptose Biosciences' Strategic Shift to Front-Line AML Therapy Garners Buy Rating
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript
Aptose Biosciences Is Maintained at Buy by HC Wainwright & Co.
Aptose Biosciences Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Maintains $23 Price Target
HC Wainwright & Co. analyst Joseph Pantginis maintains Aptose Biosciences with a Buy and maintains $23 price target.
Aptose Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 1394.67% HC Wainwright & Co. $23 → $23 Maintains Buy 02/01/2024 224.93% Piper Sandler $12 → $5
Earnings Call Summary | Aptose Biosciences(APTO.US) Q4 2023 Earnings Conference
The following is a summary of the Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript:Financial Performance:In 2023, Aptose Biosciences managed to finance its activities through various so
Aptose Biosciences GAAP EPS of -$7.58 Beats by $0.40
Aptose Biosciences Expands AML Treatment Trials
Aptose Biosciences Up 3% After Hours as Its 2023 Loss Widens on Higher R&D Spending
Aptose Biosciences (APS.TO, APTO) was up 3% in after-hours Nasdaq trading after the company on Tuesday said its annual loss widened in 2023 on higher research and development spending. The company, w
Aptose Biosciences Q4 EPS $(1.44) Beats $(1.59) Estimate
Aptose Biosciences (NASDAQ:APTO) reported quarterly losses of $(1.44) per share which beat the analyst consensus estimate of $(1.59) by 9.43 percent. This is a 12.73 percent increase over losses of $(
Recap: Aptose Biosciences Q4 Earnings
Aptose Biosciences (NASDAQ:APTO) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:02 PM.Here's what investors need to know about the announcement.EarningsAptose Biosciences beat estim
Aptose Reports FY23 Loss Per Share Of $(7.58) Vs $(6.80) Loss Last Year
Aptose Reports FY23 Loss Per Share Of $(7.58) Vs $(6.80) Loss Last Year
Analysis
Price Target
No Data
